Table 1.

Model Inputs

Parameter	Value	Ref
Probabilities
Strain Distribution
Andean Countries a
L. braziliensis	49%	[24]
L. panamensis	27%	[24]
L. guyanensis	4%	[24]
L. amazonensis	5%	[24]
Other	15%	[24]
Brazil
L. amazonensis	20%	assumption b
L. braziliensis	60%	[29]
L. guyanensis	20%	assumption b
Mexico
L. mexicana	100%	assumption b
Lifetime Risk of MCL given infection by L. braziliensis, L. panamensis, or L. guyanensis	2%	[55-57]
Lifetime Risk of DCL given infection by L. amazonensis	30% c	[58]
Cure Rates
Penatvalent antimonials (CL)	77% d	[59]
	(40-100%)
Pentavalent antimonials (MCL)	67% d	[10]
	(28-94%)
Pentamidine (MCL)	93%	[10]
Amphotericin B (MCL)	89%	[10]
Any Treatment (DCL)	(0-10%) e	[60]
Costs f
Pentavalent antimonials, CL (intralesional) g	$56.46	[61]
Pentavalent antimonials, CL (systemic)e	$169.37	[61]
Pentavalent antimonials, MCL and DCL (systemic) g	$254.06	[61]
Pentamidine	$0	[61]
Amphotericin B (MCL and DCL)	$150	[61]
Lab Materials (per visit)	$0.50	[62]

^aBolivia, Colombia, Ecuador, Peru, Venezuela

^bBased on expert opinion from Brazil

^cOverall risk of DCL following CL was 5%

^dTriangular distribution

^eUniform distribution

^fAll costs calculated using a 50kg person

^gCalculated using the average of both generic and non-generic versions of sodium stibogluconate and meglumine antimoniate